New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
04:55 EDTPTX, PTXPernix Therapeutics management to meet with Needham
Meeting to be held in New York on May 22 hosted by Needham.
News For PTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 16, 2015
07:22 EDTPTXBrean Capital to hold a summit
Subscribe for More Information
November 12, 2015
11:17 EDTPTXPernix Therapeutics says study shows silenor superior to zolpidem
Pernix Therapeutics announced interim results from a Phase IV study assessing the effects of a nighttime administration of Silenor 6 mg, zolpidem 10 mg, and placebo on arousability, gait/balance, and cognitive performance in healthy volunteers. The study assessed the effects of a single dose of Silenor 6 mg compared with matching placebo and a single dose of zolpidem 10 mg compared to its matching placebo at the respective Tmax in normal healthy adult male volunteers. The interim results of this head-to-head comparison demonstrate that Silenor 6 mg is statistically significantly superior to zolpidem 10 mg on all measures analyzed, the company said. The results also indicate that subjects taking Silenor 6 mg did not have impairment on any of these measures and were comparable to placebo. Further, Silenor 6 mg and both placebo groups were superior to zolpidem on all measures, indicating that zolpidem subjects had significant difficulty waking up, difficulty in their ability to walk, difficulty with balance, and experienced memory impairment.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use